Search Results

Business

InteRNA Technologies Establishes Clinical Advisory Board and Appoints New Members to Scientific Advisory Board

InteRNA Technologies, a clinical-stage biotech company developing microRNA -based therapeutics with a focus on cancer, announced the establishment of a Clinical Advisory Board and the appointment of new members to its Scientific Advisory Board.

October 19, 2021

·

7 min read

Business

InteRNA Appoints Established Oncology Innovator Andrea van Elsas, PhD, to its Supervisory Board

InteRNA Technologies, a clinical-stage biotech company developing microRNA -based therapeutics with a focus on cancer, announced the appointment of Andrea van Elsas, PhD, as a new member of the Company’s Supervisory Board.

October 12, 2021

·

4 min read

InteRNA Technologies Awarded € 2.7M Clinical Innovation Credit from Dutch Government

InteRNA Technologies, a clinical-stage biotech company developing microRNA -based therapeutics with a focus on cancer, announced that it was awarded a Clinical Innovation Credit of € 2.7 Million from the Dutch government.

March 11, 2021

·

3 min read

Drug Development

InteRNA Technologies Announces U.S. FDA Clearance of IND Application for Phase I Clinical Trial with Lead microRNA Candidate INT-1B3 in Patients with Advanced Solid Tumors

InteRNA Technologies announced it received Investigational New Drug clearance from the U.S. Food and Drug Administration for the company’s Phase I clinical trial evaluating lead miRNA candidate, INT-1B3, in patients with advanced solid tumors.

December 2, 2021

·

4 min read

FDA signage at its headquarters in Maryland

Artificial intelligence

FDA’s New AI Guidance Highlights Risks of Technology, Urges Early Sponsor Engagement

The FDA’s guidance on AI in drug development points to potentially life-threatening consequences of the technology, highlighting the importance of providing the regulator with detailed information regarding models’ development and maintenance.

January 7, 2025

·

2 min read

·

Tristan Manalac

InteRNA Technologies Announces Dosing of First Patient in First-in-Human Trial of microRNA Drug Candidate INT-1B3 in Patients with Advanced Solid Tumors

InteRNA Technologies announced that the first patient has been dosed in the first cohort of its first-in-human Phase I study with the Company’s lead microRNA candidate, INT-1B3.

February 16, 2021

·

3 min read

Press Releases

Join Nexalin Technology’s Exclusive Live Investor Webinar and Q&A Session, Today, January 23

January 23, 2025

·

2 min read

Press Releases

OraSure Technologies Acquires Sherlock Biosciences

December 20, 2024

·